{"title_page": "Secondary hypertension", "text_new": "{{Infobox medical condition (new)\n| name            = Secondary hypertension\n| synonyms        = \n| symptoms        = \n| complications   = \n| onset           = \n| duration        = \n| types           = \n| causes          = \n| risks           = \n| diagnosis       = \n| differential    = \n| prevention      = \n| treatment       = \n| medication      = \n| prognosis       = \n| frequency       = \n| deaths          = \n}}\n\n'''Secondary hypertension''' (or, less commonly, '''inessential hypertension''') is a type of [[hypertension]] which by definition is caused by an identifiable underlying primary cause. It is much less common than the other type, called [[essential hypertension]], affecting only 5% of hypertensive patients. It has many different causes including [[endocrine diseases]], [[kidney diseases]], and [[tumors]]. It also can be a [[Adverse effect|side effect]] of many [[medications]].\n\n==Types==\n\n===Kidney===\n\n====Renovascular hypertension====\nIt has two main causes: fibromuscular dysplasia and atherosclerosis of the renal artery resulting in stenosis.\n* ''See main article at [[Renovascular hypertension]].''\n\n====Kidney====\nOther well known causes include diseases of the [[kidney]]. This includes diseases such as [[polycystic kidney disease]] which is a [[cystic]] [[genetic disorder]] of the [[kidneys]],  [[Polycystic kidney disease|PKD]], which is characterized by the presence of multiple [[cysts]] (hence, \"polycystic\") in both [[kidneys]], can also damage the [[liver]], [[pancreas]], and rarely, the [[heart]] and [[brain]].<ref name=\"pmid19322187\">{{Cite journal|vauthors=Ecder T, Schrier RW |title=Cardiovascular abnormalities in autosomal-dominant polycystic kidney disease |journal=[[Nature Reviews Nephrology]] |volume=5 |issue=4 |pages=221\u201328 |date=April 2009 |pmid=19322187 |doi=10.1038/nrneph.2009.13 |pmc=2720315}}</ref><ref name=\"pmid18619180\">{{Cite journal|author=Gross P |title=Polycystic kidney disease: will it become treatable? |journal=[[Polskie Archiwum Medycyny Wewn\u0229trznej]] |volume=118 |issue=5 |pages=298\u2013301 |date=May 2008 |pmid=18619180 |doi= |url=http://tip.org.pl/pamw/issue/search.html?lang=en&search=18619180|accessdate=2009-06-19}}</ref><ref name=\"pmid18034588\">{{Cite journal|vauthors=Masoumi A, Reed-Gitomer B, Kelleher C, Schrier RW |title=Potential pharmacological interventions in polycystic kidney disease |journal=[[Drugs (journal)|Drugs]] |volume=67 |issue=17 |pages=2495\u2013510 |year=2007 |pmid=18034588 |doi= 10.2165/00003495-200767170-00004|url= }}</ref><ref name=\"pmid17429048\">{{Cite journal|author=Chapman AB |title=Autosomal dominant polycystic kidney disease: time for a change? |journal=[[Journal of the American Society of Nephrology]] |volume=18 |issue=5 |pages=1399\u2013407 |date=May 2007 |pmid=17429048 |doi=10.1681/ASN.2007020155 |url=http://jasn.asnjournals.org/cgi/pmidlookup?view=long&pmid=17429048|accessdate=2009-06-19}}</ref>\nIt can be [[autosomal dominant]] or [[autosomal recessive]], with the autosomal dominant form being more common and characterized by progressive cyst development and bilaterally enlarged kidneys with multiple cysts, with concurrent development of hypertension, [[chronic kidney disease]] and [[kidney]] pain.<ref name=\"pmid18579674\">{{Cite journal|author=Chapman AB |title=Approaches to testing new treatments in autosomal dominant polycystic kidney disease: insights from the CRISP and HALT-PKD studies |journal=[[Clinical Journal of the American Society of Nephrology]] |volume=3 |issue=4 |pages=1197\u2013204 |date=July 2008 |pmid=18579674 |doi=10.2215/CJN.00060108 |url=http://cjasn.asnjournals.org/cgi/pmidlookup?view=long&pmid=18579674|accessdate=2009-06-19}}</ref> Or chronic [[glomerulonephritis]] which is a disease characterized by [[inflammation]] of the [[glomerulus|glomeruli]], or small [[blood vessel]]s in the kidneys.<ref name=\"pmid18222341\">{{Cite journal|vauthors=Berthoux FC, Mohey H, Afiani A |title=Natural history of primary IgA nephropathy |journal=[[Seminars in Nephrology]] |volume=28 |issue=1 |pages=4\u20139 |date=January 2008 |pmid=18222341 |doi=10.1016/j.semnephrol.2007.10.001 |url=http://journals.elsevierhealth.com/retrieve/pii/S0270-9295(07)00139-8|accessdate=2009-06-19}}</ref><ref name=\"pmid19171112\">{{Cite journal|author=D'Cruz D |title=Renal manifestations of the antiphospholipid syndrome |journal=[[Current Rheumatology Reports]] |volume=11 |issue=1 |pages=52\u201360 |date=February 2009 |pmid=19171112 |doi= 10.1007/s11926-009-0008-2|url= }}</ref><ref name=\"pmid19190809\">{{Cite journal|vauthors=Licht C, Fremeaux-Bacchi V |title=Hereditary and acquired complement dysregulation in membranoproliferative glomerulonephritis |journal=[[Thrombosis and Haemostasis]] |volume=101 |issue=2 |pages=271\u201378 |date=February 2009 |pmid=19190809 |doi= 10.1160/th08-09-0575|url=http://www.schattauer.de/index.php?id=1268&pii=th09020271&no_cache=1|accessdate=2009-06-19}}</ref>\n\nHypertension can also be produced by diseases of the [[renal artery|renal arteries]] supplying the kidney. This is known as [[renovascular hypertension]]; it is thought that decreased perfusion of renal tissue due to [[stenosis]] of a main or branch renal artery activates the [[renin\u2013angiotensin system]].<ref name=\"pmid19427501\">{{Cite journal|author=Textor SC |title=Current Approaches to Renovascular Hypertension |journal=[[The Medical Clinics of North America]] |volume=93 |issue=3 |pages=717\u201332, Table of Contents |date=May 2009 |pmid=19427501 |doi=10.1016/j.mcna.2009.02.012 |url=http://journals.elsevierhealth.com/retrieve/pii/S0025-7125(09)00028-5|accessdate=2009-06-19 |pmc=2752469}}</ref><ref name=\"pmid19096816\">{{Cite journal|vauthors=Voiculescu A, Rump LC |title=[Hypertension in patients with renal artery stenosis] |language=German |journal=[[Der Internist]] |volume=50 |issue=1 |pages=42\u201350 |date=January 2009 |pmid=19096816 |doi=10.1007/s00108-008-2198-5}}</ref><ref name=\"pmid18805381\">{{Cite journal|vauthors=Kendrick J, Chonchol M |title=Renal artery stenosis and chronic ischemic nephropathy: epidemiology and diagnosis |journal=[[Advances in Chronic Kidney Disease]] |volume=15 |issue=4 |pages=355\u201362 |date=October 2008 |pmid=18805381 |doi=10.1053/j.ackd.2008.07.004 }}</ref>\n\nAlso, some [[kidney cancer|renal tumors]] can cause hypertension.  The [[differential diagnosis]] of a renal tumor in a young patient with hypertension includes [[Juxtaglomerular cell tumor]], [[Wilms' tumor]], and [[renal cell carcinoma]], all of which may produce renin.<ref name=\"pmid19098017\">{{Cite journal|vauthors=M\u00e9ndez GP, Klock C, Nos\u00e9 V | title = Juxtaglomerular Cell Tumor of the Kidney: Case Report and Differential Diagnosis With Emphasis on Pathologic and Cytopathologic Features| journal = Int. J. Surg. Pathol.| volume = 19| issue = 1| pages = 93\u201398|date=December 2008| pmid = 19098017| doi = 10.1177/1066896908329413}}</ref>\n\n====Hypertension secondary to other renal disorders====\n* [[Chronic kidney disease]]\n* [[Kidney disease]] / [[renal artery stenosis]] \u2013  the normal physiological response to low blood pressure in the renal arteries is to increase cardiac output (CO) to maintain the pressure needed for [[glomerulus (kidney)|glomerular filtration]]. Here, however, increased CO cannot solve the structural problems causing renal artery hypotension, with the result that CO remains chronically elevated.\n* [[Renal segmental hypoplasia]] (Ask-Upmark kidney)\n\n===Hypertension secondary to endocrine disorders===\n* Neurogenic hypertension \u2013 excessive secretion of norepinephrine and epinephrine which promotes [[vasoconstriction]] resulting from chronic high activity of the [[Autonomic nervous system|sympathoadrenal system]], the [[sympathetic nervous system]] and the [[adrenal gland]]. The specific mechanism involved is increased release of the \"stress hormones\", [[epinephrine]] (adrenaline) and [[norepinephrine]] which increase blood output from the heart and constrict arteries. People with neurogenic hypertension respond poorly to treatment with diuretics as the underlying cause of their hypertension is not addressed.<ref name=AJH1003>{{cite journal|title=Neurogenic essential hypertension revisited: the case for increased clinical and research attention|journal=[[American Journal of Hypertension]] |date=2003|volume=16|issue=10|pages=881\u201388|doi=10.1016/S0895-7061(03)00978-6|pmid=14553971 |author=Samuel J Mann}}</ref>\n** [[Pheochromocytoma]] \u2013 a tumor which results in an excessive secretion of norepinephrine and epinephrine which promotes vasoconstriction\n* [[Hyperaldosteronism]] ([[Conn's syndrome]])   \u2013 idiopathic hyperaldosteronism, liddle's syndrome (also called pseudoaldosteronism), glucocorticoid remediable aldosteronism\n* [[Cushing's syndrome]] \u2013 an excessive secretion of glucocorticoids causes the hypertension\n* [[Hyperparathyroidism]]\n* [[Acromegaly]]\n* [[Hyperthyroidism]]\n* [[Hypothyroidism]]\n\n====Adrenal====\nA variety of adrenal cortical abnormalities can cause hypertension, In primary [[aldosteronism]] there is a clear relationship between the aldosterone-induced sodium retention and the hypertension.<ref name=\"pmid19356005\">{{Cite journal|vauthors=Giacchetti G, Turchi F, Boscaro M, Ronconi V |title=Management of primary aldosteronism: its complications and their outcomes after treatment |journal=[[Current Vascular Pharmacology]] |volume=7 |issue=2 |pages=244\u201349 |date=April 2009 |pmid=19356005 |doi= 10.2174/157016109787455716}}</ref>\n\n[[Congenital adrenal hyperplasia]], a group of autosomal recessive disorders of the enzymes responsible for steroid hormone production, can lead to secondary hypertension by creating atypically high levels of [[mineralocorticoid]] steroid hormones.  These mineralocorticoids cross-react with the aldosterone receptor, activating it and raising blood pressure.\n\n* [[Congenital adrenal hyperplasia due to 17 alpha-hydroxylase deficiency|17 alpha-hydroxylase deficiency]] causes an inability to produce cortisol.  Instead, extremely high levels of the precursor hormone corticosterone are produced, some of which is converted to [[11-Deoxycorticosterone]] (DOC), a potent mineralocorticoid not normally clinically important in humans.  DOC has blood-pressure raising effects similar to aldosterone, and abnormally high levels result in [[Hypokalemia|hypokalemic]] hypertension.<ref>{{Cite journal | url=http://emedicine.medscape.com/article/117140-overview#a5 |title = C-17 Hydroxylase Deficiency: Practice Essentials, Pathophysiology, Epidemiology|date = February 2018}}</ref>\n* [[11\u03b2-hydroxylase deficiency]], aka [[apparent mineralocorticoid excess syndrome]], involves a defect in the gene for [[11\u03b2-hydroxysteroid dehydrogenase]], an enzyme that normally inactivates circulating [[cortisol]] to the less-active metabolite [[cortisone]].<ref name=\"pmid18032795\">{{Cite journal|author=Bailey MA |title=A Switch in the Mechanism of Hypertension in the Syndrome of Apparent Mineralocorticoid Excess |journal=[[Journal of the American Society of Nephrology]] |volume=19 |issue=1 |pages=47\u201358 |date=January 2008 |pmid=18032795 |pmc=2391031 |doi=10.1681/ASN.2007040401 |name-list-format=vanc|author2=Paterson JM|author3=Hadoke PW|display-authors=3|last4=Wrobel|first4=N.|last5=Bellamy|first5=C. O.C.|last6=Brownstein|first6=D. G.|last7=Seckl|first7=J. R.|last8=Mullins|first8=J. J.}}</ref>   At high concentrations [[cortisol]] can cross-react and activate the [[mineralocorticoid]] receptor, leading to [[aldosterone]]-like effects in the [[kidney]], causing hypertension.<ref name=\"pmid17368420\">{{Cite journal|vauthors=Vantyghem MC, Marcelli-Tourvieille S, Defrance F, Wemeau JL |title=11beta-hydroxysteroide dehydrogenases. Recent advances |language=French |journal=[[Annales d'endocrinologie]] |volume=68 |issue=5 |pages=349\u201356 |date=October 2007 |pmid=17368420 |doi=10.1016/j.ando.2007.02.003}}</ref> This effect can also be produced by prolonged ingestion of [[liquorice]] (which can be of potent strength in [[Liquorice (confectionery)|liquorice candy]]), by causing inhibition of the [[11\u03b2-hydroxysteroid dehydrogenase]] enzyme and likewise leading to secondary [[apparent mineralocorticoid excess]] syndrome.<ref name=\"pmid17314322\">{{Cite journal|author=Atanasov AG |title=Impaired protein stability of 11beta-hydroxysteroid dehydrogenase type 2: a novel mechanism of apparent mineralocorticoid excess |journal=[[Journal of the American Society of Nephrology]] |volume=18 |issue=4 |pages=1262\u201370 |date=April 2007 |pmid=17314322 |doi=10.1681/ASN.2006111235 |url=http://jasn.asnjournals.org/cgi/pmidlookup?view=long&pmid=17314322|accessdate=2009-06-19|name-list-format=vanc|author2=Ignatova ID|author3=Nashev LG|display-authors=3|last4=Dick|first4=B.|last5=Ferrari|first5=P.|last6=Frey|first6=F. J.|last7=Odermatt|first7=A.}}</ref><ref name=\"pmid19166646\">{{Cite journal|author=Johns C |title=Glycyrrhizic acid toxicity caused by consumption of licorice candy cigars |journal=[[Canadian Journal of Emergency Medical Care]] |volume=11 |issue=1 |pages=94\u201396 |date=January 2009 |pmid=19166646 |doi= 10.1017/s1481803500010988}}</ref><ref>{{Cite journal|vauthors=Sontia B, Mooney J, Gaudet L, Touyz RM |title=Pseudohyperaldosteronism, liquorice, and hypertension |journal=[[Journal of Clinical Hypertension]] |volume=10 |issue=2 |pages=153\u201357 |date=February 2008 |pmid=18256580 |doi= 10.1111/j.1751-7176.2008.07470.x}}</ref> Frequently, if liquorice is the cause of the high blood pressure, a low blood level of potassium will also be present.<ref name=\"pmid19166646\"/> Cortisol induced hypertension cannot be completely explained by the activity of Cortisol on Aldosterone receptors. Experiments show that treatment with [[Spironolactone]] (an inhibitor of the aldosterone receptor), does not prevent hypertension with excess cortisol. It seems that inhibition of [[nitric oxide]] synthesis may also play a role in cortisol induced hypertension.<ref name=\"Whitworth et al\">{{cite journal|last1=Whitworth|first1=Judith|title=Cardiovascular Consequences of Cortisol Excess|journal=Vasc Health Risk Manag|date=Dec 2015|volume=1|issue=4|pages=291\u201399|pmc=1993964|pmid=17315601|doi=10.2147/vhrm.2005.1.4.291}}</ref>\n\nYet another related disorder causing hypertension is [[glucocorticoid remediable aldosteronism]], which is an [[autosomal dominant]] disorder in which the increase in [[aldosterone]] secretion produced by [[ACTH]] is no longer transient, causing of [[primary hyperaldosteronism]], the [[Gene]] mutated will result in an [[aldosterone synthase]] that is [[ACTH]]-sensitive, which is normally not.<ref name=\"pmid19171690\">{{Cite journal|author=Escher G |title=Hyperaldosteronism in pregnancy |journal=[[Therapeutic Advances in Cardiovascular Disease]] |volume=3 |issue=2 |pages=123\u201332 |date=April 2009 |pmid=19171690 |doi=10.1177/1753944708100180 }}</ref><ref name=\"pmid18622235\">{{Cite journal|author=Sukor N |title=Further evidence for linkage of familial hyperaldosteronism type II at chromosome 7p22 in Italian as well as Australian and South American families |journal=[[Journal of Hypertension]] |volume=26 |issue=8 |pages=1577\u201382 |date=August 2008 |pmid=18622235 |doi=10.1097/HJH.0b013e3283028352 |name-list-format=vanc|author2=Mulatero P|author3=Gordon RD|display-authors=3|last4=So|first4=Albertina|last5=Duffy|first5=David|last6=Bertello|first6=Chiara|last7=Kelemen|first7=Livia|last8=Jeske|first8=Yvette|last9=Veglio|first9=Franco}}</ref><ref name=\"pmid16776234\">{{Cite journal|vauthors=Omura M, Nishikawa T |title=[Glucocorticoid remediable aldosteronism] |language=Japanese |journal=[[Nippon Rinsho]] |volume=Suppl 1 |issue= |pages=628\u201334 |date=May 2006 |pmid=16776234 |doi= |url= }}</ref><ref name=\"pmid15931322\">{{Cite journal|author=Luft FC |title=Mendelian Forms of Human Hypertension and Mechanisms of Disease |journal=[[Clinical Medicine & Research]] |volume=1 |issue=4 |pages=291\u2013300 |date=October 2003 |pmid=15931322 |pmc=1069058 |doi= 10.3121/cmr.1.4.291}}</ref><ref name=\"pmid15062555\">{{Cite journal|vauthors=Nicod J, Dick B, Frey FJ, Ferrari P |title=Mutation analysis of CYP11B1 and CYP11B2 in patients with increased 18-hydroxycortisol production |journal=[[Molecular and Cellular Endocrinology]] |volume=214 |issue=1\u20132 |pages=167\u201374 |date=February 2004 |pmid=15062555 |doi=10.1016/j.mce.2003.10.056 }}</ref> [[glucocorticoid remediable aldosteronism|GRA]] appears to be the most common [[monogenic (genetics)|monogenic]] form of human hypertension.<ref name=\"pmid14667264\">{{Cite journal|vauthors=McMahon GT, Dluhy RG |title=Glucocorticoid-remediable aldosteronism |journal=[[Cardiology in Review]] |volume=12 |issue=1 |pages=44\u201348 |year=2004 |pmid=14667264 |doi=10.1097/01.crd.0000096417.42861.ce }}</ref>\n\nCompare these effects to those seen in [[Conn's disease]], an [[adrenocortical tumor]] which causes excess release of aldosterone,<ref name=\"pmid18777504\">{{Cite journal|vauthors=Ziaja J, Cholewa K, Mazurek U, Cierpka L |title=[Molecular basics of aldosterone and cortisol synthesis in normal adrenals and adrenocortical adenomas] |language=Polish |journal=[[Endokrynologia Polska]] |volume=59 |issue=4 |pages=330\u201339 |year=2008 |pmid=18777504 |doi= |url= }}</ref> that leads to hypertension.<ref name=\"pmid15985978\">{{Cite journal|author=Astegiano M |title=Association between Crohn's disease and Conn's syndrome. A report of two cases |journal=[[Panminerva Medica]] |volume=47 |issue=1 |pages=61\u20134 |date=March 2005 |pmid=15985978 |doi= |url=|name-list-format=vanc|author2=Bresso F|author3=Demarchi B|display-authors=3|last4=Sapone|first4=N|last5=Novero|first5=D|last6=Palestro|first6=G|last7=Resegotti|first7=A|last8=Pellicano|first8=R|last9=Rizzetto|first9=M }}</ref><ref name=\"pmid15761535\">{{Cite journal|author=Pereira RM |title=[Childhood adrenocortical tumors] |language=Portuguese |journal=[[Arquivos Brasileiros de Endocrinologia e Metabologia]] |volume=48 |issue=5 |pages=651\u201358 |date=October 2004 |pmid=15761535 |name-list-format=vanc|author2=Michalkiewicz E|author3=Sandrini F|display-authors=3|doi=10.1590/S0004-27302004000500010|last4=Figueiredo|first4=BC|last5=Pianovski|first5=M|last6=Fran\u00e7a|first6=SN|last7=Boguszewski|first7=MC|last8=Costa|first8=O|last9=Cat|first9=I }}</ref><ref name=\"pmid10732265\">{{Cite journal|vauthors=Kievit J, Haak HR |title=Diagnosis and treatment of adrenal incidentaloma. A cost-effectiveness analysis |journal=[[Endocrinology and Metabolism Clinics of North America]] |volume=29 |issue=1 |pages=69\u201390, viii\u2013ix |date=March 2000 |pmid=10732265 |doi= 10.1016/S0889-8529(05)70117-1|url= }}</ref>\n\nAnother adrenal related cause is [[Cushing's syndrome]] which is a disorder caused by high levels of [[cortisol]]. Cortisol is a [[hormone]] secreted by the [[adrenal cortex|cortex]] of the [[adrenal glands]]. Cushing's syndrome can be caused by taking [[glucocorticoid]] drugs, or by tumors that produce cortisol or [[adrenocorticotropic hormone]] (ACTH).<ref>Kumar, Abbas, Fausto. ''Robbins and Cotran Pathologic Basis of Disease, 7th ed.'' Elsevier-Saunders; New York, 2005.</ref> More than 80% of patients with Cushing's syndrome develop hypertension.,<ref name=\"pmid19096817\">{{Cite journal|vauthors=Dodt C, Wellh\u00f6ner JP, Sch\u00fctt M, Sayk F |title=[Glucocorticoids and hypertension] |language=German |journal=[[Der Internist]] |volume=50 |issue=1 |pages=36\u201341 |date=January 2009 |pmid=19096817 |doi=10.1007/s00108-008-2197-6}}</ref> which is accompanied by distinct symptoms of the syndrome, such as [[central obesity]], [[lipodystrophy]], [[moon face]], [[sweating]], [[hirsutism]] and [[anxiety]].<ref>{{Cite book|title=The American Psychiatric Publishing Textbook of Neuropsychiatry and Behavioral Neurosciences |last=Yudofsky |first=Stuart C. |author2=Robert E. Hales  |edition=5th |year=2007 |publisher=American Psychiatric Pub, Inc. |isbn=978-1-58562-239-9 }}</ref>\n\n[[Neuroendocrine]] tumors are also a well known cause of secondary hypertension. [[Pheochromocytoma]]<ref name=\"pmid19158054\">{{Cite journal|vauthors=Kassim TA, Clarke DD, Mai VQ, Clyde PW, Mohamed Shakir KM |title=Catecholamine-induced cardiomyopathy |journal=[[Endocrine Practice]] |volume=14 |issue=9 |pages=1137\u201349 |date=December 2008 |pmid=19158054 |doi= 10.4158/ep.14.9.1137|url=http://aace.metapress.com/openurl.asp?genre=article&issn=1530-891X&volume=14&issue=9&spage=1137|accessdate=2009-06-19}}</ref> (most often located in the [[adrenal medulla]]) increases secretion of [[catecholamines]] such as [[epinephrine]] and [[norepinephrine]], causing excessive stimulation of [[adrenergic receptors]], which results in peripheral [[vasoconstriction]] and cardiac stimulation. This diagnosis is confirmed by demonstrating increased urinary excretion of epinephrine and norepinephrine and/or their [[metabolite]]s ([[vanillylmandelic acid]]).\n\n===Other secondary hypertension===\n*[[Hormonal contraceptives]]\n*[[Neurologic disorders]]\n*[[Obstructive sleep apnea]]\n*[[Liquorice]] (when consumed in excessive amounts)\n*[[Scleroderma]]\n*[[Neurofibromatosis]]\n* [[Pregnancy]]: unclear cause.\n* [[Cancers]]: tumours in the kidney can operate in the same way as kidney disease. More commonly, however, tumors cause inessential hypertension by ectopic secretion of hormones involved in normal physiological control of blood pressure.\n* [[Medication|Drugs]]: In particular, [[alcohol (drug)|alcohol]], nasal decongestants with adrenergic effects, [[Non-steroidal anti-inflammatory drug|NSAID]]s, [[Monoamine oxidase inhibitor|MAOI]]s, [[Adrenergic receptor|adrenoceptor]] stimulants, and combined methods of [[hormonal contraception]] (those containing [[ethinylestradiol]]) can cause hypertension while in use.\n**Heavy [[alcoholic beverage|alcohol]] use\n**[[Steroid]] use\n**[[Nicotine]] use.<ref name=\"jnc7\" />\n* Malformed [[aorta]], [[slow pulse]], [[ischemia]]: these cause reduced blood flow to the renal arteries, with physiological responses as already outlined.\n**[[Coarcation of the aorta|Coarctation of the aorta]]\n**[[Atherosclerosis]]\n* [[Anemia]]: unclear cause.\n* [[Fever]]: unclear cause.\n* [[White coat hypertension]], that is, elevated blood pressure in a clinical setting but not in other settings, probably due to the anxiety some people experience during a clinic visit.\n* ''Perioperative hypertension'' is development of hypertension just before, during or after [[surgery]]. It may occur before surgery during the induction of [[anesthesia]]; intraoperatively e.g. by pain-induced [[sympathetic nervous system]] stimulation; in the early postanesthesia period, e.g. by pain-induced sympathetic stimulation, [[hypothermia]], [[Hypoxia (medical)|hypoxia]], or [[hypervolemia]] from excessive intraoperative fluid therapy; and in the 24 to 48 hours after the postoperative period as fluid is mobilized from the extravascular space. In addition, hypertension may develop perioperatively because of discontinuation of long-term antihypertensive medication.<ref>{{Cite journal|vauthors=Varon J, Marik PE |title=Perioperative hypertension management |journal=Vasc Health Risk Manag |volume=4 |issue=3 |pages=615\u201327 |year=2008 |pmid=18827911 |pmc=2515421 |doi= 10.2147/VHRM.S2471|url=}}</ref>\n\n===Medication side effects===\nCertain medications, including [[Non-steroidal anti-inflammatory drug|NSAID]]s (Motrin/[[Ibuprofen]]) and steroids can cause hypertension.<ref name=\"isbn0-9757919-2-3\">{{Cite book|editor=Simone Rossi |title=Australian medicines handbook 2006 |publisher=Australian Medicines Handbook Pty Ltd |location=[[Adelaide]] |year=2006 |pages= |isbn=978-0-9757919-2-9 }}{{Page needed|date=September 2010}}</ref><ref name=\"pmid19393824\">{{Cite journal|author=White WB |title=Defining the problem of treating the patient with hypertension and arthritis pain |journal=[[The American Journal of Medicine]] |volume=122 |issue=5 Suppl |pages=S3\u20139 |date=May 2009 |pmid=19393824 |doi=10.1016/j.amjmed.2009.03.002 }}</ref><ref name=\"pmid19007428\">{{Cite journal|vauthors=Mackenzie IS, Rutherford D, MacDonald TM |title=Nitric oxide and cardiovascular effects: new insights in the role of nitric oxide for the management of osteoarthritis |journal=[[Arthritis Research & Therapy]] |volume=10 Suppl 2 |issue= Suppl 2|page=S3 |year=2008 |pmid=19007428 |pmc=2582806 |doi=10.1186/ar2464 }}</ref><ref name=\"pmid19007426\">{{Cite journal|author=Berenbaum F |title=New horizons and perspectives in the treatment of osteoarthritis |journal=[[Arthritis Research & Therapy]] |volume=10 Suppl 2 |issue= Suppl 2|page=S1 |year=2008 |pmid=19007426 |pmc=2582808 |doi=10.1186/ar2462 }}</ref><ref name=\"pmid18760760\">{{Cite journal|vauthors=Akinbamowo AO, Salzberg DJ, Weir MR |title=Renal consequences of prostaglandin inhibition in heart failure |journal=[[Heart Failure Clinics]] |volume=4 |issue=4 |pages=505\u201310 |date=October 2008 |pmid=18760760 |doi=10.1016/j.hfc.2008.03.002 }}</ref> Other medications include extrogens (such as those found in oral contraceptives with high estrogenic activity), certain antidepressants (such as [[venlafaxine]]), [[buspirone]], [[carbamazepine]], [[bromocriptine]], [[clozapine]], and [[cyclosporine]].<ref name=\"jnc7\">{{cite journal | url=http://jama.ama-assn.org/cgi/content/full/289.19.2560v1 | author=Chobanian AV |journal=[[Journal of the American Medical Association|JAMA]] | title=The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report | year=2003 | volume=289 | pages=2560\u201372 | pmid=12748199 | doi=10.1001/jama.289.19.2560 | issue=19 |name-list-format=vanc | display-authors=1 | last2=Bakris | first2=G. L. | last3=Black | first3=H. R. | last4=Cushman | first4=W. C. | last5=Green | first5=L. A. | last6=Izzo | first6=J. L. | last7=Jones | first7=D. W. | last8=Materson | first8=B. J. | last9=Oparil | first9=S.}}</ref>\nHigh blood pressure that is associated with the sudden [[Drug withdrawal|withdrawal]] of various [[antihypertensive]] medications is called rebound hypertension.<ref name=\"pmid6101302\">{{Cite journal|author=Lowenstein J |title=Drugs five years later: clonidine |journal=[[Annals of Internal Medicine]] |volume=92 |issue=1 |pages=74\u201377 |date=January 1980 |pmid=6101302 |doi= 10.7326/0003-4819-92-1-74|url= }}</ref><ref name=\"pmid9050985\">{{Cite journal|author=Robertson JI |title=Risk factors and drugs in the treatment of hypertension |journal=[[Journal of Hypertension Supplement]] |volume=15 |issue=1 |pages=S43\u20136 |date=January 1997 |pmid=9050985 |doi= 10.1097/00004872-199715011-00006|url= }}</ref><ref name=\"pmid10489097\">{{Cite journal|author=Schachter M |title=Moxonidine: a review of safety and tolerability after seven years of clinical experience |journal=[[Journal of Hypertension Supplement]] |volume=17 |issue=3 |pages=S37\u20139 |date=August 1999 |pmid=10489097 |doi= |url= }}</ref><ref name=\"pmid7677385\">{{Cite journal|vauthors=Sch\u00e4fer SG, Kaan EC, Christen MO, L\u00f6w-Kr\u00f6ger A, Mest HJ, Molderings GJ |title=Why imidazoline receptor modulator in the treatment of hypertension? |journal=[[Annals of the New York Academy of Sciences]] |volume=763 |issue= 1|pages=659\u201372 |date=July 1995 |pmid=7677385 |doi= 10.1111/j.1749-6632.1995.tb32460.x|bibcode=1995NYASA.763..659S }}</ref><ref name=\"pmid7785759\">{{Cite journal|vauthors=Larsen R, Kleinschmidt S |title=[Controlled hypotension] |language=German |journal=[[Der Anaesthesist]] |volume=44 |issue=4 |pages=291\u2013308 |date=April 1995 |pmid=7785759 |doi= 10.1007/s001010050157|url= }}</ref><ref name=\"pmid3006469\">{{Cite journal|author=Scholtysik G |title=Animal pharmacology of guanfacine |journal=[[The American Journal of Cardiology]] |volume=57 |issue=9 |pages=13E\u201317E |date=March 1986 |pmid=3006469 |doi= 10.1016/0002-9149(86)90717-4|url= }}</ref><ref name=\"pmid343894\">{{Cite journal|author=Myers MG |title=New drugs in hypertension |journal=[[Canadian Medical Association Journal]] |volume=116 |issue=2 |pages=173\u201376 |date=January 1977 |pmid=343894 |pmc=1879000 |doi= |url= }}</ref>  The increases in blood pressure may result in blood pressures greater than when the medication was initiated. Depending on the severity of the increase in blood pressure, rebound hypertension may result in a [[hypertensive emergency]]. Rebound hypertension is avoided by gradually reducing the dose (also known as \"dose tapering\"), thereby giving the body enough time to adjust to reduction in dose. Medications commonly associated with rebound hypertension include centrally-acting antihypertensive agents, such as [[clonidine]]<ref name=\"pmid6094346\">{{Cite journal|vauthors=van Zwieten PA, Thoolen MJ, Timmermans PB |title=The hypotensive activity and side effects of methyldopa, clonidine, and guanfacine |journal=Hypertension |volume=6 |issue=5 Pt 2 |pages=II28\u201333 |year=1984 |pmid=6094346 |doi= 10.1161/01.hyp.6.5_pt_2.ii28|url= }}</ref> and methyl-dopa.<ref name=\"pmid343894\"/>\n\nOther herbal or \"natural products\" which have been associated with hypertension include [[Ephedra|ma huang]], [[Hypericum perforatum|St John's wort]], and licorice.<ref name=\"jnc7\" />\n\n===Pregnancy===\nFew women of childbearing age have high blood pressure, up to 11% develop [[hypertension of pregnancy]].<ref name=\"pmid18979429\">{{Cite journal|vauthors=Kang A, Struben H |title=[Pre-eclampsia screening in first and second trimester] |language=German |journal=[[Therapeutische Umschau]] |volume=65 |issue=11 |pages=663\u201366 |date=November 2008 |pmid=18979429 |doi=10.1024/0040-5930.65.11.663 |url= }}</ref> While generally benign, it may herald three complications of pregnancy: [[pre-eclampsia]], [[HELLP syndrome]] and [[eclampsia]]. Follow-up and control with medication is therefore often necessary.<ref name=\"pmid19332964\">{{Cite journal|author=Marik PE |title=Hypertensive disorders of pregnancy |journal=[[Postgraduate Medicine]] |volume=121 |issue=2 |pages=69\u201376 |date=March 2009 |pmid=19332964 |doi=10.3810/pgm.2009.03.1978 |url=http://www.postgradmed.com/index.php?art=pgm_03_2009?article=1978|accessdate=2009-06-18}}</ref><ref name=\"pmid19250798\">{{Cite journal|vauthors=Mounier-Vehier C, Delsart P |title=[Pregnancy-related hypertension: a cardiovascular risk situation] |language=French |journal=[[Presse M\u00e9dicale]] |volume=38 |issue=4 |pages=600\u201308 |date=April 2009 |pmid=19250798 |doi=10.1016/j.lpm.2008.11.018 |url=http://www.masson.fr/masson/S0755-4982(09)00045-1|accessdate=2009-06-18}}</ref>\n\n===Sleep disturbances===\nAnother common and under-recognized cause of hypertension is [[sleep apnea]],<ref name=\"pmid19249449\">{{Cite journal|vauthors=Pack AI, Gislason T |title=Obstructive sleep apnea and cardiovascular disease: a perspective and future directions |journal=[[Progress in Cardiovascular Diseases]] |volume=51 |issue=5 |pages=434\u201351 |year=2009 |pmid=19249449 |doi=10.1016/j.pcad.2009.01.002 }}</ref><ref name=\"Sleep Apnea\">{{Cite journal|url=http://www.aafp.org/afp/20020115/229.html|vauthors=Silverberg DS, Iaina A, Oksenberg A |journal=American Family Physician|title=Treating Obstructive Sleep Apnea Improves Essential Hypertension and Quality of Life|date=January 2002|volume = 65|issue = 2|pages = 229\u201336|pmid = 11820487}}</ref> which is often best treated with nocturnal nasal continuous positive airway pressure (CPAP), but other approaches include the [[Mandibular advancement splint]] (MAS), UPPP, [[tonsillectomy]], [[adenoidectomy]], [[septoplasty]], or weight loss.\nAnother cause is an exceptionally rare [[neurological disease]] called [[Binswanger's disease]], causing [[dementia]]; it is a rare form of [[multi-infarct dementia]], and is one of the neurological [[syndromes]] associated with hypertension.<ref name=\"pmid19198127\">{{Cite journal|vauthors=Tomimoto H, Ihara M, Takahashi R, Fukuyama H |title=[Functional imaging in Binswanger's disease] |language=Japanese |journal=[[Rinsho Shinkeigaku]] |volume=48 |issue=11 |pages=947\u201350 |date=November 2008 |pmid=19198127 |doi= 10.5692/clinicalneurol.48.947|url= }}</ref>\n\n===Arsenic exposure===\nBecause of the ubiquity of arsenic in ground water supplies and its effect on cardiovascular health, low dose [[arsenic poisoning]] should be inferred as a part of the pathogenesis of idiopathic hypertension. Idiopathic and essential are both somewhat synonymous with primary hypertension. Arsenic exposure has also many of the same signs of primary hypertension such as [[headache]], [[somnolence]],\n<ref>Arsenic trioxide drugs dot com</ref>\n[[confusion]], [[proteinuria]]\n<ref>atsdr-medical management guidelines for arsenic trioxide</ref>\n[[visual disturbances]], and [[nausea]] and [[vomiting]]\n<ref>Arsenic Author: Frances M Dyro, MD, Chief of the Neuromuscular Section, Associate Professor, Department of Neurology, New York Medical College, Westchester Medical Center</ref>\n\n===Potassium deficiency===\nDue to the role of intracellular potassium in regulation of cellular pressures related to sodium, establishing potassium balance has been shown to reverse hypertension.\n<ref>{{cite journal |author=Addison WL |title=The Use of Sodium Chloride, Potassium Chloride, Sodium Bromide, and Potassium Bromide in Cases of Arterial Hypertension which are Amenable to Potassium Chloride |journal=Can Med Assoc J |volume=18 |issue=3 |pages=281\u201385 |date=March 1928 |pmid=20316740 |pmc=1710082 |doi= |url=}}</ref>\n\n==Diagnosis==\nThe ABCDE mnemonic can be used to help determine a secondary cause of hypertension\n* A: Accuracy, Apnea, Aldosteronism\n* B: Bruits, Bad Kidney\n* C: Catecholamines, Coarctation of the Aorta, Cushing's Syndrome\n* D: Drugs, Diet\n* E: Erythropoietin, Endocrine Disorders <ref name=AMN>{{Cite web | title =Secondary Hypertension | publisher=Armenian Medical Network | work =Hypertension Etiology & Classification - Secondary Hypertension | url=http://www.health.am/hypertension/secondary-hypertension/ | year = 2006 | accessdate=2007-12-02 | authors =Williams B et al.; British Hypertension Society; Michael Sutters, MD}}</ref>\n\n==References==\n{{Reflist}}\n\n== External links ==\n{{Medical resources\n|  ICD10 = {{ICD10|I|15||i|10}} \n|  ICD9  = {{ICD9|405}}\n}}\n\n{{Vascular diseases}}\n{{Use dmy dates|date=April 2020}}\n\n{{Authority control}}\n\n{{DEFAULTSORT:Secondary Hypertension}}\n[[Category:Kidney diseases]]\n[[Category:Hypertension]]\n", "text_old": "{{Infobox medical condition (new)\n| name            = Secondary hypertension\n| synonyms        = \n| symptoms        = \n| complications   = \n| onset           = \n| duration        = \n| types           = \n| causes          = \n| risks           = \n| diagnosis       = \n| differential    = \n| prevention      = \n| treatment       = \n| medication      = \n| prognosis       = \n| frequency       = \n| deaths          = \n}}\n\n'''Secondary hypertension''' (or, less commonly, '''inessential hypertension''') is a type of [[hypertension]] which by definition is caused by an identifiable underlying primary cause. It is much less common than the other type, called [[essential hypertension]], affecting only 5% of hypertensive patients. It has many different causes including [[endocrine diseases]], [[kidney diseases]], and [[tumors]]. It also can be a [[Adverse effect|side effect]] of many [[medications]].\n\n==Types==\n\n===Kidney===\n\n====Renovascular hypertension====\nIt has two main causes: fibromuscular dysplasia and atherosclerosis of the renal artery resulting in stenosis.\n* ''See main article at [[Renovascular hypertension]].''\n\n====Kidney====\nOther well known causes include diseases of the [[kidney]]. This includes diseases such as [[polycystic kidney disease]] which is a [[cystic]] [[genetic disorder]] of the [[kidneys]],  [[Polycystic kidney disease|PKD]], which is characterized by the presence of multiple [[cysts]] (hence, \"polycystic\") in both [[kidneys]], can also damage the [[liver]], [[pancreas]], and rarely, the [[heart]] and [[brain]].<ref name=\"pmid19322187\">{{Cite journal|vauthors=Ecder T, Schrier RW |title=Cardiovascular abnormalities in autosomal-dominant polycystic kidney disease |journal=[[Nature Reviews Nephrology]] |volume=5 |issue=4 |pages=221\u201328 |date=April 2009 |pmid=19322187 |doi=10.1038/nrneph.2009.13 |pmc=2720315}}</ref><ref name=\"pmid18619180\">{{Cite journal|author=Gross P |title=Polycystic kidney disease: will it become treatable? |journal=[[Polskie Archiwum Medycyny Wewn\u0229trznej]] |volume=118 |issue=5 |pages=298\u2013301 |date=May 2008 |pmid=18619180 |doi= |url=http://tip.org.pl/pamw/issue/search.html?lang=en&search=18619180|accessdate=2009-06-19}}</ref><ref name=\"pmid18034588\">{{Cite journal|vauthors=Masoumi A, Reed-Gitomer B, Kelleher C, Schrier RW |title=Potential pharmacological interventions in polycystic kidney disease |journal=[[Drugs (journal)|Drugs]] |volume=67 |issue=17 |pages=2495\u2013510 |year=2007 |pmid=18034588 |doi= 10.2165/00003495-200767170-00004|url= }}</ref><ref name=\"pmid17429048\">{{Cite journal|author=Chapman AB |title=Autosomal dominant polycystic kidney disease: time for a change? |journal=[[Journal of the American Society of Nephrology]] |volume=18 |issue=5 |pages=1399\u2013407 |date=May 2007 |pmid=17429048 |doi=10.1681/ASN.2007020155 |url=http://jasn.asnjournals.org/cgi/pmidlookup?view=long&pmid=17429048|accessdate=2009-06-19}}</ref>\nIt can be [[autosomal dominant]] or [[autosomal recessive]], with the autosomal dominant form being more common and characterized by progressive cyst development and bilaterally enlarged kidneys with multiple cysts, with concurrent development of hypertension, [[chronic kidney disease]] and [[kidney]] pain.<ref name=\"pmid18579674\">{{Cite journal|author=Chapman AB |title=Approaches to testing new treatments in autosomal dominant polycystic kidney disease: insights from the CRISP and HALT-PKD studies |journal=[[Clinical Journal of the American Society of Nephrology]] |volume=3 |issue=4 |pages=1197\u2013204 |date=July 2008 |pmid=18579674 |doi=10.2215/CJN.00060108 |url=http://cjasn.asnjournals.org/cgi/pmidlookup?view=long&pmid=18579674|accessdate=2009-06-19}}</ref> Or chronic [[glomerulonephritis]] which is a disease characterized by [[inflammation]] of the [[glomerulus|glomeruli]], or small [[blood vessel]]s in the kidneys.<ref name=\"pmid18222341\">{{Cite journal|vauthors=Berthoux FC, Mohey H, Afiani A |title=Natural history of primary IgA nephropathy |journal=[[Seminars in Nephrology]] |volume=28 |issue=1 |pages=4\u20139 |date=January 2008 |pmid=18222341 |doi=10.1016/j.semnephrol.2007.10.001 |url=http://journals.elsevierhealth.com/retrieve/pii/S0270-9295(07)00139-8|accessdate=2009-06-19}}</ref><ref name=\"pmid19171112\">{{Cite journal|author=D'Cruz D |title=Renal manifestations of the antiphospholipid syndrome |journal=[[Current Rheumatology Reports]] |volume=11 |issue=1 |pages=52\u201360 |date=February 2009 |pmid=19171112 |doi= 10.1007/s11926-009-0008-2|url= }}</ref><ref name=\"pmid19190809\">{{Cite journal|vauthors=Licht C, Fremeaux-Bacchi V |title=Hereditary and acquired complement dysregulation in membranoproliferative glomerulonephritis |journal=[[Thrombosis and Haemostasis]] |volume=101 |issue=2 |pages=271\u201378 |date=February 2009 |pmid=19190809 |doi= 10.1160/th08-09-0575|url=http://www.schattauer.de/index.php?id=1268&pii=th09020271&no_cache=1|accessdate=2009-06-19}}</ref>\n\nHypertension can also be produced by diseases of the [[renal artery|renal arteries]] supplying the kidney. This is known as [[renovascular hypertension]]; it is thought that decreased perfusion of renal tissue due to [[stenosis]] of a main or branch renal artery activates the [[renin\u2013angiotensin system]].<ref name=\"pmid19427501\">{{Cite journal|author=Textor SC |title=Current Approaches to Renovascular Hypertension |journal=[[The Medical Clinics of North America]] |volume=93 |issue=3 |pages=717\u201332, Table of Contents |date=May 2009 |pmid=19427501 |doi=10.1016/j.mcna.2009.02.012 |url=http://journals.elsevierhealth.com/retrieve/pii/S0025-7125(09)00028-5|accessdate=2009-06-19 |pmc=2752469}}</ref><ref name=\"pmid19096816\">{{Cite journal|vauthors=Voiculescu A, Rump LC |title=[Hypertension in patients with renal artery stenosis] |language=German |journal=[[Der Internist]] |volume=50 |issue=1 |pages=42\u201350 |date=January 2009 |pmid=19096816 |doi=10.1007/s00108-008-2198-5}}</ref><ref name=\"pmid18805381\">{{Cite journal|vauthors=Kendrick J, Chonchol M |title=Renal artery stenosis and chronic ischemic nephropathy: epidemiology and diagnosis |journal=[[Advances in Chronic Kidney Disease]] |volume=15 |issue=4 |pages=355\u201362 |date=October 2008 |pmid=18805381 |doi=10.1053/j.ackd.2008.07.004 }}</ref>\n\nAlso, some [[kidney cancer|renal tumors]] can cause hypertension.  The [[differential diagnosis]] of a renal tumor in a young patient with hypertension includes [[Juxtaglomerular cell tumor]], [[Wilms' tumor]], and [[renal cell carcinoma]], all of which may produce renin.<ref name=\"pmid19098017\">{{Cite journal|vauthors=M\u00e9ndez GP, Klock C, Nos\u00e9 V | title = Juxtaglomerular Cell Tumor of the Kidney: Case Report and Differential Diagnosis With Emphasis on Pathologic and Cytopathologic Features| journal = Int. J. Surg. Pathol.| volume = 19| issue = 1| pages = 93\u201398|date=December 2008| pmid = 19098017| doi = 10.1177/1066896908329413}}</ref>\n\n====Hypertension secondary to other renal disorders====\n* [[Chronic kidney disease]]\n* [[Kidney disease]] / [[renal artery stenosis]] \u2013  the normal physiological response to low blood pressure in the renal arteries is to increase cardiac output (CO) to maintain the pressure needed for [[glomerulus (kidney)|glomerular filtration]]. Here, however, increased CO cannot solve the structural problems causing renal artery hypotension, with the result that CO remains chronically elevated.\n* [[Renal segmental hypoplasia]] (Ask-Upmark kidney)\n\n===Hypertension secondary to endocrine disorders===\n* Neurogenic hypertension \u2013 excessive secretion of norepinephrine and epinephrine which promotes [[vasoconstriction]] resulting from chronic high activity of the [[Autonomic nervous system|sympathoadrenal system]], the [[sympathetic nervous system]] and the [[adrenal gland]]. The specific mechanism involved is increased release of the \"stress hormones\", [[epinephrine]] (adrenaline) and [[norepinephrine]] which increase blood output from the heart and constrict arteries. People with neurogenic hypertension respond poorly to treatment with diuretics as the underlying cause of their hypertension is not addressed.<ref name=AJH1003>{{cite journal|title=Neurogenic essential hypertension revisited: the case for increased clinical and research attention|journal=[[American Journal of Hypertension]] |date=2003|volume=16|issue=10|pages=881\u201388|doi=10.1016/S0895-7061(03)00978-6|pmid=14553971 |author=Samuel J Mann}}</ref>\n** [[Pheochromocytoma]] \u2013 a tumor which results in an excessive secretion of norepinephrine and epinephrine which promotes vasoconstriction\n* [[Hyperaldosteronism]] ([[Conn's syndrome]])   \u2013 idiopathic hyperaldosteronism, liddle's syndrome (also called pseudoaldosteronism), glucocorticoid remediable aldosteronism\n* [[Cushing's syndrome]] \u2013 an excessive secretion of glucocorticoids causes the hypertension\n* [[Hyperparathyroidism]]\n* [[Acromegaly]]\n* [[Hyperthyroidism]]\n* [[Hypothyroidism]]\n\n====Adrenal====\nA variety of adrenal cortical abnormalities can cause hypertension, In primary [[aldosteronism]] there is a clear relationship between the aldosterone-induced sodium retention and the hypertension.<ref name=\"pmid19356005\">{{Cite journal|vauthors=Giacchetti G, Turchi F, Boscaro M, Ronconi V |title=Management of primary aldosteronism: its complications and their outcomes after treatment |journal=[[Current Vascular Pharmacology]] |volume=7 |issue=2 |pages=244\u201349 |date=April 2009 |pmid=19356005 |doi= 10.2174/157016109787455716}}</ref>\n\n[[Congenital adrenal hyperplasia]], a group of autosomal recessive disorders of the enzymes responsible for steroid hormone production, can lead to secondary hypertension by creating atypically high levels of [[mineralocorticoid]] steroid hormones.  These mineralocorticoids cross-react with the aldosterone receptor, activating it and raising blood pressure.\n\n* [[Congenital adrenal hyperplasia due to 17 alpha-hydroxylase deficiency|17 alpha-hydroxylase deficiency]] causes an inability to produce cortisol.  Instead, extremely high levels of the precursor hormone corticosterone are produced, some of which is converted to [[11-Deoxycorticosterone]] (DOC), a potent mineralocorticoid not normally clinically important in humans.  DOC has blood-pressure raising effects similar to aldosterone, and abnormally high levels result in [[Hypokalemia|hypokalemic]] hypertension.<ref>{{Cite journal | url=http://emedicine.medscape.com/article/117140-overview#a5 |title = C-17 Hydroxylase Deficiency: Practice Essentials, Pathophysiology, Epidemiology|date = February 2018}}</ref>\n* [[11\u03b2-hydroxylase deficiency]], aka [[apparent mineralocorticoid excess syndrome]], involves a defect in the gene for [[11\u03b2-hydroxysteroid dehydrogenase]], an enzyme that normally inactivates circulating [[cortisol]] to the less-active metabolite [[cortisone]].<ref name=\"pmid18032795\">{{Cite journal|author=Bailey MA |title=A Switch in the Mechanism of Hypertension in the Syndrome of Apparent Mineralocorticoid Excess |journal=[[Journal of the American Society of Nephrology]] |volume=19 |issue=1 |pages=47\u201358 |date=January 2008 |pmid=18032795 |pmc=2391031 |doi=10.1681/ASN.2007040401 |name-list-format=vanc|author2=Paterson JM|author3=Hadoke PW|display-authors=3|last4=Wrobel|first4=N.|last5=Bellamy|first5=C. O.C.|last6=Brownstein|first6=D. G.|last7=Seckl|first7=J. R.|last8=Mullins|first8=J. J.}}</ref>   At high concentrations [[cortisol]] can cross-react and activate the [[mineralocorticoid]] receptor, leading to [[aldosterone]]-like effects in the [[kidney]], causing hypertension.<ref name=\"pmid17368420\">{{Cite journal|vauthors=Vantyghem MC, Marcelli-Tourvieille S, Defrance F, Wemeau JL |title=11beta-hydroxysteroide dehydrogenases. Recent advances |language=French |journal=[[Annales d'endocrinologie]] |volume=68 |issue=5 |pages=349\u201356 |date=October 2007 |pmid=17368420 |doi=10.1016/j.ando.2007.02.003}}</ref> This effect can also be produced by prolonged ingestion of [[liquorice]] (which can be of potent strength in [[Liquorice (confectionery)|liquorice candy]]), by causing inhibition of the [[11\u03b2-hydroxysteroid dehydrogenase]] enzyme and likewise leading to secondary [[apparent mineralocorticoid excess]] syndrome.<ref name=\"pmid17314322\">{{Cite journal|author=Atanasov AG |title=Impaired protein stability of 11beta-hydroxysteroid dehydrogenase type 2: a novel mechanism of apparent mineralocorticoid excess |journal=[[Journal of the American Society of Nephrology]] |volume=18 |issue=4 |pages=1262\u201370 |date=April 2007 |pmid=17314322 |doi=10.1681/ASN.2006111235 |url=http://jasn.asnjournals.org/cgi/pmidlookup?view=long&pmid=17314322|accessdate=2009-06-19|name-list-format=vanc|author2=Ignatova ID|author3=Nashev LG|display-authors=3|last4=Dick|first4=B.|last5=Ferrari|first5=P.|last6=Frey|first6=F. J.|last7=Odermatt|first7=A.}}</ref><ref name=\"pmid19166646\">{{Cite journal|author=Johns C |title=Glycyrrhizic acid toxicity caused by consumption of licorice candy cigars |journal=[[Canadian Journal of Emergency Medical Care]] |volume=11 |issue=1 |pages=94\u201396 |date=January 2009 |pmid=19166646 |doi= 10.1017/s1481803500010988}}</ref><ref>{{Cite journal|vauthors=Sontia B, Mooney J, Gaudet L, Touyz RM |title=Pseudohyperaldosteronism, liquorice, and hypertension |journal=[[Journal of Clinical Hypertension]] |volume=10 |issue=2 |pages=153\u201357 |date=February 2008 |pmid=18256580 |doi= 10.1111/j.1751-7176.2008.07470.x}}</ref> Frequently, if liquorice is the cause of the high blood pressure, a low blood level of potassium will also be present.<ref name=\"pmid19166646\"/> Cortisol induced hypertension cannot be completely explained by the activity of Cortisol on Aldosterone receptors. Experiments show that treatment with [[Spironolactone]] (an inhibitor of the aldosterone receptor), does not prevent hypertension with excess cortisol. It seems that inhibition of [[nitric oxide]] synthesis may also play a role in cortisol induced hypertension.<ref name=\"Whitworth et al\">{{cite journal|last1=Whitworth|first1=Judith|title=Cardiovascular Consequences of Cortisol Excess|journal=Vasc Health Risk Manag|date=Dec 2015|volume=1|issue=4|pages=291\u201399|pmc=1993964|pmid=17315601|doi=10.2147/vhrm.2005.1.4.291}}</ref>\n\nYet another related disorder causing hypertension is [[glucocorticoid remediable aldosteronism]], which is an [[autosomal dominant]] disorder in which the increase in [[aldosterone]] secretion produced by [[ACTH]] is no longer transient, causing of [[primary hyperaldosteronism]], the [[Gene]] mutated will result in an [[aldosterone synthase]] that is [[ACTH]]-sensitive, which is normally not.<ref name=\"pmid19171690\">{{Cite journal|author=Escher G |title=Hyperaldosteronism in pregnancy |journal=[[Therapeutic Advances in Cardiovascular Disease]] |volume=3 |issue=2 |pages=123\u201332 |date=April 2009 |pmid=19171690 |doi=10.1177/1753944708100180 }}</ref><ref name=\"pmid18622235\">{{Cite journal|author=Sukor N |title=Further evidence for linkage of familial hyperaldosteronism type II at chromosome 7p22 in Italian as well as Australian and South American families |journal=[[Journal of Hypertension]] |volume=26 |issue=8 |pages=1577\u201382 |date=August 2008 |pmid=18622235 |doi=10.1097/HJH.0b013e3283028352 |name-list-format=vanc|author2=Mulatero P|author3=Gordon RD|display-authors=3|last4=So|first4=Albertina|last5=Duffy|first5=David|last6=Bertello|first6=Chiara|last7=Kelemen|first7=Livia|last8=Jeske|first8=Yvette|last9=Veglio|first9=Franco}}</ref><ref name=\"pmid16776234\">{{Cite journal|vauthors=Omura M, Nishikawa T |title=[Glucocorticoid remediable aldosteronism] |language=Japanese |journal=[[Nippon Rinsho]] |volume=Suppl 1 |issue= |pages=628\u201334 |date=May 2006 |pmid=16776234 |doi= |url= }}</ref><ref name=\"pmid15931322\">{{Cite journal|author=Luft FC |title=Mendelian Forms of Human Hypertension and Mechanisms of Disease |journal=[[Clinical Medicine & Research]] |volume=1 |issue=4 |pages=291\u2013300 |date=October 2003 |pmid=15931322 |pmc=1069058 |doi= 10.3121/cmr.1.4.291}}</ref><ref name=\"pmid15062555\">{{Cite journal|vauthors=Nicod J, Dick B, Frey FJ, Ferrari P |title=Mutation analysis of CYP11B1 and CYP11B2 in patients with increased 18-hydroxycortisol production |journal=[[Molecular and Cellular Endocrinology]] |volume=214 |issue=1\u20132 |pages=167\u201374 |date=February 2004 |pmid=15062555 |doi=10.1016/j.mce.2003.10.056 }}</ref> [[glucocorticoid remediable aldosteronism|GRA]] appears to be the most common [[monogenic (genetics)|monogenic]] form of human hypertension.<ref name=\"pmid14667264\">{{Cite journal|vauthors=McMahon GT, Dluhy RG |title=Glucocorticoid-remediable aldosteronism |journal=[[Cardiology in Review]] |volume=12 |issue=1 |pages=44\u201348 |year=2004 |pmid=14667264 |doi=10.1097/01.crd.0000096417.42861.ce }}</ref>\n\nCompare these effects to those seen in [[Conn's disease]], an [[adrenocortical tumor]] which causes excess release of aldosterone,<ref name=\"pmid18777504\">{{Cite journal|vauthors=Ziaja J, Cholewa K, Mazurek U, Cierpka L |title=[Molecular basics of aldosterone and cortisol synthesis in normal adrenals and adrenocortical adenomas] |language=Polish |journal=[[Endokrynologia Polska]] |volume=59 |issue=4 |pages=330\u201339 |year=2008 |pmid=18777504 |doi= |url= }}</ref> that leads to hypertension.<ref name=\"pmid15985978\">{{Cite journal|author=Astegiano M |title=Association between Crohn's disease and Conn's syndrome. A report of two cases |journal=[[Panminerva Medica]] |volume=47 |issue=1 |pages=61\u20134 |date=March 2005 |pmid=15985978 |doi= |url=|name-list-format=vanc|author2=Bresso F|author3=Demarchi B|display-authors=3|last4=Sapone|first4=N|last5=Novero|first5=D|last6=Palestro|first6=G|last7=Resegotti|first7=A|last8=Pellicano|first8=R|last9=Rizzetto|first9=M }}</ref><ref name=\"pmid15761535\">{{Cite journal|author=Pereira RM |title=[Childhood adrenocortical tumors] |language=Portuguese |journal=[[Arquivos Brasileiros de Endocrinologia e Metabologia]] |volume=48 |issue=5 |pages=651\u201358 |date=October 2004 |pmid=15761535 |name-list-format=vanc|author2=Michalkiewicz E|author3=Sandrini F|display-authors=3|doi=10.1590/S0004-27302004000500010|last4=Figueiredo|first4=BC|last5=Pianovski|first5=M|last6=Fran\u00e7a|first6=SN|last7=Boguszewski|first7=MC|last8=Costa|first8=O|last9=Cat|first9=I }}</ref><ref name=\"pmid10732265\">{{Cite journal|vauthors=Kievit J, Haak HR |title=Diagnosis and treatment of adrenal incidentaloma. A cost-effectiveness analysis |journal=[[Endocrinology and Metabolism Clinics of North America]] |volume=29 |issue=1 |pages=69\u201390, viii\u2013ix |date=March 2000 |pmid=10732265 |doi= 10.1016/S0889-8529(05)70117-1|url= }}</ref>\n\nAnother adrenal related cause is [[Cushing's syndrome]] which is a disorder caused by high levels of [[cortisol]]. Cortisol is a [[hormone]] secreted by the [[adrenal cortex|cortex]] of the [[adrenal glands]]. Cushing's syndrome can be caused by taking [[glucocorticoid]] drugs, or by tumors that produce cortisol or [[adrenocorticotropic hormone]] (ACTH).<ref>Kumar, Abbas, Fausto. ''Robbins and Cotran Pathologic Basis of Disease, 7th ed.'' Elsevier-Saunders; New York, 2005.</ref> More than 80% of patients with Cushing's syndrome develop hypertension.,<ref name=\"pmid19096817\">{{Cite journal|vauthors=Dodt C, Wellh\u00f6ner JP, Sch\u00fctt M, Sayk F |title=[Glucocorticoids and hypertension] |language=German |journal=[[Der Internist]] |volume=50 |issue=1 |pages=36\u201341 |date=January 2009 |pmid=19096817 |doi=10.1007/s00108-008-2197-6}}</ref> which is accompanied by distinct symptoms of the syndrome, such as [[central obesity]], [[lipodystrophy]], [[moon face]], [[sweating]], [[hirsutism]] and [[anxiety]].<ref>{{Cite book|title=The American Psychiatric Publishing Textbook of Neuropsychiatry and Behavioral Neurosciences |last=Yudofsky |first=Stuart C. |author2=Robert E. Hales  |edition=5th |year=2007 |publisher=American Psychiatric Pub, Inc. |isbn=978-1-58562-239-9 }}</ref>\n\n[[Neuroendocrine]] tumors are also a well known cause of secondary hypertension. [[Pheochromocytoma]]<ref name=\"pmid19158054\">{{Cite journal|vauthors=Kassim TA, Clarke DD, Mai VQ, Clyde PW, Mohamed Shakir KM |title=Catecholamine-induced cardiomyopathy |journal=[[Endocrine Practice]] |volume=14 |issue=9 |pages=1137\u201349 |date=December 2008 |pmid=19158054 |doi= 10.4158/ep.14.9.1137|url=http://aace.metapress.com/openurl.asp?genre=article&issn=1530-891X&volume=14&issue=9&spage=1137|accessdate=2009-06-19}}</ref> (most often located in the [[adrenal medulla]]) increases secretion of [[catecholamines]] such as [[epinephrine]] and [[norepinephrine]], causing excessive stimulation of [[adrenergic receptors]], which results in peripheral [[vasoconstriction]] and cardiac stimulation. This diagnosis is confirmed by demonstrating increased urinary excretion of epinephrine and norepinephrine and/or their [[metabolite]]s ([[vanillylmandelic acid]]).\n\n===Other secondary hypertension===\n*[[Hormonal contraceptives]]\n*[[Neurologic disorders]]\n*[[Obstructive sleep apnea]]\n*[[Liquorice]] (when consumed in excessive amounts)\n*[[Scleroderma]]\n*[[Neurofibromatosis]]\n* [[Pregnancy]]: unclear cause.\n* [[Cancers]]: tumours in the kidney can operate in the same way as kidney disease. More commonly, however, tumors cause inessential hypertension by ectopic secretion of hormones involved in normal physiological control of blood pressure.\n* [[Medication|Drugs]]: In particular, [[alcohol (drug)|alcohol]], nasal decongestants with adrenergic effects, [[Non-steroidal anti-inflammatory drug|NSAID]]s, [[Monoamine oxidase inhibitor|MAOI]]s, [[Adrenergic receptor|adrenoceptor]] stimulants, and combined methods of [[hormonal contraception]] (those containing [[ethinylestradiol]]) can cause hypertension while in use.\n**Heavy [[alcoholic beverage|alcohol]] use\n**[[Steroid]] use\n**[[Nicotine]] use.<ref name=\"jnc7\" />\n* Malformed [[aorta]], [[slow pulse]], [[ischemia]]: these cause reduced blood flow to the renal arteries, with physiological responses as already outlined.\n**[[Coarcation of the aorta|Coarctation of the aorta]]\n**[[Atherosclerosis]]\n* [[Anemia]]: unclear cause.\n* [[Fever]]: unclear cause.\n* [[White coat hypertension]], that is, elevated blood pressure in a clinical setting but not in other settings, probably due to the anxiety some people experience during a clinic visit.\n* ''Perioperative hypertension'' is development of hypertension just before, during or after [[surgery]]. It may occur before surgery during the induction of [[anesthesia]]; intraoperatively e.g. by pain-induced [[sympathetic nervous system]] stimulation; in the early postanesthesia period, e.g. by pain-induced sympathetic stimulation, [[hypothermia]], [[Hypoxia (medical)|hypoxia]], or [[hypervolemia]] from excessive intraoperative fluid therapy; and in the 24 to 48 hours after the postoperative period as fluid is mobilized from the extravascular space. In addition, hypertension may develop perioperatively because of discontinuation of long-term antihypertensive medication.<ref>{{Cite journal|vauthors=Varon J, Marik PE |title=Perioperative hypertension management |journal=Vasc Health Risk Manag |volume=4 |issue=3 |pages=615\u201327 |year=2008 |pmid=18827911 |pmc=2515421 |doi= 10.2147/VHRM.S2471|url=}}</ref>\n\n===Medication side effects===\nCertain medications, including [[Non-steroidal anti-inflammatory drug|NSAID]]s (Motrin/[[Ibuprofen]]) and steroids can cause hypertension.<ref name=\"isbn0-9757919-2-3\">{{Cite book|editor=Simone Rossi |title=Australian medicines handbook 2006 |publisher=Australian Medicines Handbook Pty Ltd |location=[[Adelaide]] |year=2006 |pages= |isbn=978-0-9757919-2-9 }}{{Page needed|date=September 2010}}</ref><ref name=\"pmid19393824\">{{Cite journal|author=White WB |title=Defining the problem of treating the patient with hypertension and arthritis pain |journal=[[The American Journal of Medicine]] |volume=122 |issue=5 Suppl |pages=S3\u20139 |date=May 2009 |pmid=19393824 |doi=10.1016/j.amjmed.2009.03.002 }}</ref><ref name=\"pmid19007428\">{{Cite journal|vauthors=Mackenzie IS, Rutherford D, MacDonald TM |title=Nitric oxide and cardiovascular effects: new insights in the role of nitric oxide for the management of osteoarthritis |journal=[[Arthritis Research & Therapy]] |volume=10 Suppl 2 |issue= Suppl 2|page=S3 |year=2008 |pmid=19007428 |pmc=2582806 |doi=10.1186/ar2464 }}</ref><ref name=\"pmid19007426\">{{Cite journal|author=Berenbaum F |title=New horizons and perspectives in the treatment of osteoarthritis |journal=[[Arthritis Research & Therapy]] |volume=10 Suppl 2 |issue= Suppl 2|page=S1 |year=2008 |pmid=19007426 |pmc=2582808 |doi=10.1186/ar2462 }}</ref><ref name=\"pmid18760760\">{{Cite journal|vauthors=Akinbamowo AO, Salzberg DJ, Weir MR |title=Renal consequences of prostaglandin inhibition in heart failure |journal=[[Heart Failure Clinics]] |volume=4 |issue=4 |pages=505\u201310 |date=October 2008 |pmid=18760760 |doi=10.1016/j.hfc.2008.03.002 }}</ref> Other medications include extrogens (such as those found in oral contraceptives with high estrogenic activity), certain antidepressants (such as [[venlafaxine]]), [[buspirone]], [[carbamazepine]], [[bromocriptine]], [[clozapine]], and [[cyclosporine]].<ref name=\"jnc7\">{{cite journal | url=http://jama.ama-assn.org/cgi/content/full/289.19.2560v1 | author=Chobanian AV |journal=[[Journal of the American Medical Association|JAMA]] | title=The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report | year=2003 | volume=289 | pages=2560\u201372 | pmid=12748199 | doi=10.1001/jama.289.19.2560 | issue=19 |name-list-format=vanc | display-authors=1 | last2=Bakris | first2=G. L. | last3=Black | first3=H. R. | last4=Cushman | first4=W. C. | last5=Green | first5=L. A. | last6=Izzo | first6=J. L. | last7=Jones | first7=D. W. | last8=Materson | first8=B. J. | last9=Oparil | first9=S.}}</ref>\nHigh blood pressure that is associated with the sudden [[Drug withdrawal|withdrawal]] of various [[antihypertensive]] medications is called rebound hypertension.<ref name=\"pmid6101302\">{{Cite journal|author=Lowenstein J |title=Drugs five years later: clonidine |journal=[[Annals of Internal Medicine]] |volume=92 |issue=1 |pages=74\u201377 |date=January 1980 |pmid=6101302 |doi= 10.7326/0003-4819-92-1-74|url= }}</ref><ref name=\"pmid9050985\">{{Cite journal|author=Robertson JI |title=Risk factors and drugs in the treatment of hypertension |journal=[[Journal of Hypertension Supplement]] |volume=15 |issue=1 |pages=S43\u20136 |date=January 1997 |pmid=9050985 |doi= 10.1097/00004872-199715011-00006|url= }}</ref><ref name=\"pmid10489097\">{{Cite journal|author=Schachter M |title=Moxonidine: a review of safety and tolerability after seven years of clinical experience |journal=[[Journal of Hypertension Supplement]] |volume=17 |issue=3 |pages=S37\u20139 |date=August 1999 |pmid=10489097 |doi= |url= }}</ref><ref name=\"pmid7677385\">{{Cite journal|vauthors=Sch\u00e4fer SG, Kaan EC, Christen MO, L\u00f6w-Kr\u00f6ger A, Mest HJ, Molderings GJ |title=Why imidazoline receptor modulator in the treatment of hypertension? |journal=[[Annals of the New York Academy of Sciences]] |volume=763 |issue= 1|pages=659\u201372 |date=July 1995 |pmid=7677385 |doi= 10.1111/j.1749-6632.1995.tb32460.x|bibcode=1995NYASA.763..659S }}</ref><ref name=\"pmid7785759\">{{Cite journal|vauthors=Larsen R, Kleinschmidt S |title=[Controlled hypotension] |language=German |journal=[[Der Anaesthesist]] |volume=44 |issue=4 |pages=291\u2013308 |date=April 1995 |pmid=7785759 |doi= 10.1007/s001010050157|url= }}</ref><ref name=\"pmid3006469\">{{Cite journal|author=Scholtysik G |title=Animal pharmacology of guanfacine |journal=[[The American Journal of Cardiology]] |volume=57 |issue=9 |pages=13E\u201317E |date=March 1986 |pmid=3006469 |doi= 10.1016/0002-9149(86)90717-4|url= }}</ref><ref name=\"pmid343894\">{{Cite journal|author=Myers MG |title=New drugs in hypertension |journal=[[Canadian Medical Association Journal]] |volume=116 |issue=2 |pages=173\u201376 |date=January 1977 |pmid=343894 |pmc=1879000 |doi= |url= }}</ref>  The increases in blood pressure may result in blood pressures greater than when the medication was initiated. Depending on the severity of the increase in blood pressure, rebound hypertension may result in a [[hypertensive emergency]]. Rebound hypertension is avoided by gradually reducing the dose (also known as \"dose tapering\"), thereby giving the body enough time to adjust to reduction in dose. Medications commonly associated with rebound hypertension include centrally-acting antihypertensive agents, such as [[clonidine]]<ref name=\"pmid6094346\">{{Cite journal|vauthors=van Zwieten PA, Thoolen MJ, Timmermans PB |title=The hypotensive activity and side effects of methyldopa, clonidine, and guanfacine |journal=Hypertension |volume=6 |issue=5 Pt 2 |pages=II28\u201333 |year=1984 |pmid=6094346 |doi= 10.1161/01.hyp.6.5_pt_2.ii28|url= }}</ref> and methyl-dopa.<ref name=\"pmid343894\"/>\n\nOther herbal or \"natural products\" which have been associated with hypertension include [[Ephedra|ma huang]], [[Hypericum perforatum|St John's wort]], and licorice.<ref name=\"jnc7\" />\n\n===Pregnancy===\nFew women of childbearing age have high blood pressure, up to 11% develop [[hypertension of pregnancy]].<ref name=\"pmid18979429\">{{Cite journal|vauthors=Kang A, Struben H |title=[Pre-eclampsia screening in first and second trimester] |language=German |journal=[[Therapeutische Umschau]] |volume=65 |issue=11 |pages=663\u201366 |date=November 2008 |pmid=18979429 |doi=10.1024/0040-5930.65.11.663 |url= }}</ref> While generally benign, it may herald three complications of pregnancy: [[pre-eclampsia]], [[HELLP syndrome]] and [[eclampsia]]. Follow-up and control with medication is therefore often necessary.<ref name=\"pmid19332964\">{{Cite journal|author=Marik PE |title=Hypertensive disorders of pregnancy |journal=[[Postgraduate Medicine]] |volume=121 |issue=2 |pages=69\u201376 |date=March 2009 |pmid=19332964 |doi=10.3810/pgm.2009.03.1978 |url=http://www.postgradmed.com/index.php?art=pgm_03_2009?article=1978|accessdate=2009-06-18}}</ref><ref name=\"pmid19250798\">{{Cite journal|vauthors=Mounier-Vehier C, Delsart P |title=[Pregnancy-related hypertension: a cardiovascular risk situation] |language=French |journal=[[Presse M\u00e9dicale]] |volume=38 |issue=4 |pages=600\u201308 |date=April 2009 |pmid=19250798 |doi=10.1016/j.lpm.2008.11.018 |url=http://www.masson.fr/masson/S0755-4982(09)00045-1|accessdate=2009-06-18}}</ref>\n\n===Sleep disturbances===\nAnother common and under-recognized cause of hypertension is [[sleep apnea]],<ref name=\"pmid19249449\">{{Cite journal|vauthors=Pack AI, Gislason T |title=Obstructive sleep apnea and cardiovascular disease: a perspective and future directions |journal=[[Progress in Cardiovascular Diseases]] |volume=51 |issue=5 |pages=434\u201351 |year=2009 |pmid=19249449 |doi=10.1016/j.pcad.2009.01.002 }}</ref><ref name=\"Sleep Apnea\">{{Cite journal|url=http://www.aafp.org/afp/20020115/229.html|vauthors=Silverberg DS, Iaina A, Oksenberg A |journal=American Family Physician|title=Treating Obstructive Sleep Apnea Improves Essential Hypertension and Quality of Life|date=January 2002|volume = 65|issue = 2|pages = 229\u201336|pmid = 11820487}}</ref> which is often best treated with nocturnal nasal continuous positive airway pressure (CPAP), but other approaches include the [[Mandibular advancement splint]] (MAS), UPPP, [[tonsillectomy]], [[adenoidectomy]], [[septoplasty]], or weight loss.\nAnother cause is an exceptionally rare [[neurological disease]] called [[Binswanger's disease]], causing [[dementia]]; it is a rare form of [[multi-infarct dementia]], and is one of the neurological [[syndromes]] associated with hypertension.<ref name=\"pmid19198127\">{{Cite journal|vauthors=Tomimoto H, Ihara M, Takahashi R, Fukuyama H |title=[Functional imaging in Binswanger's disease] |language=Japanese |journal=[[Rinsho Shinkeigaku]] |volume=48 |issue=11 |pages=947\u201350 |date=November 2008 |pmid=19198127 |doi= 10.5692/clinicalneurol.48.947|url= }}</ref>\n\n===Arsenic exposure===\nBecause of the ubiquity of arsenic in ground water supplies and its effect on cardiovascular health, low dose [[arsenic poisoning]] should be inferred as a part of the pathogenesis of idiopathic hypertension. Idiopathic and essential are both somewhat synonymous with primary hypertension. Arsenic exposure has also many of the same signs of primary hypertension such as [[headache]], [[somnolence]],\n<ref>Arsenic trioxide drugs dot com</ref>\n[[confusion]], [[proteinuria]]\n<ref>atsdr-medical management guidelines for arsenic trioxide</ref>\n[[visual disturbances]], and [[nausea]] and [[vomiting]]\n<ref>Arsenic Author: Frances M Dyro, MD, Chief of the Neuromuscular Section, Associate Professor, Department of Neurology, New York Medical College, Westchester Medical Center</ref>\n\n===Potassium deficiency===\nDue to the role of intracellular potassium in regulation of cellular pressures related to sodium, establishing potassium balance has been shown to reverse hypertension.\n<ref>{{cite journal |author=Addison WL |title=The Use of Sodium Chloride, Potassium Chloride, Sodium Bromide, and Potassium Bromide in Cases of Arterial Hypertension which are Amenable to Potassium Chloride |journal=Can Med Assoc J |volume=18 |issue=3 |pages=281\u201385 |date=March 1928 |pmid=20316740 |pmc=1710082 |doi= |url=}}</ref>\n\n==Diagnosis==\nThe ABCDE mnemonic can be used to help determine a secondary cause of hypertension\n* A: Accuracy, Apnea, Aldosteronism\n* B: Bruits, Bad Kidney\n* C: Catecholamines, Coarctation of the Aorta, Cushing's Syndrome\n* D: Drugs, Diet\n* E: Erythropoietin, Endocrine Disorders <ref name=AMN>{{Cite web | title =Secondary Hypertension | publisher=Armenian Medical Network | work =Hypertension Etiology & Classification - Secondary Hypertension | url=http://www.health.am/hypertension/secondary-hypertension/ | year = 2006 | accessdate=2007-12-02 | authors =Williams B et al.; British Hypertension Society; Michael Sutters, MD}}</ref>\n\n==References==\n{{Reflist}}\n\n== External links ==\n{{Medical resources\n|  ICD10 = {{ICD10|I|15||i|10}} \n|  ICD9  = {{ICD9|405}}\n}}\n\n{{Vascular diseases}}\n{{Use dmy dates|date=September 2010}}\n\n{{DEFAULTSORT:Secondary Hypertension}}\n[[Category:Kidney diseases]]\n[[Category:Hypertension]]\n", "name_user": "Rich Farmbrough", "label": "safe", "comment": "\u2192\u200eExternal links:Update date format tag", "url_page": "//en.wikipedia.org/wiki/Secondary_hypertension"}
